AcelRx Pharmaceuticals Company Profile (NASDAQ:ACRX)

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals logoAcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ACRX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.72
  • 50 Day Moving Average: $3.44
  • 200 Day Moving Average: $3.29
  • 52-Week Range: $2.40 - $5.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.63
  • P/E Growth: 0.00
  • Market Cap: $176.26M
  • Outstanding Shares: 45,312,000
  • Beta: 2.21
Profitability:
  • Net Margins: -111.47%
  • Return on Equity: -94.98%
  • Return on Assets: -21.14%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 5.02%
  • Quick Ratio: 4.96%
Additional Links:
Companies Related to AcelRx Pharmaceuticals:

Analyst Ratings

Consensus Ratings for AcelRx Pharmaceuticals (NASDAQ:ACRX) (?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $8.20 (111.34% upside)

Analysts' Ratings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/28/2016HC WainwrightReiterated RatingBuy$7.00View Rating Details
9/15/2016Roth CapitalBoost Price TargetBuy$11.25 -> $15.00View Rating Details
8/16/2016RBC Capital MarketsReiterated RatingPositive$6.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyView Rating Details
8/5/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
7/29/2016Cowen and CompanyReiterated RatingHoldView Rating Details
5/6/2016Seaport Global SecuritiesUpgradeAccumulate -> BuyView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details
10/30/2015Royal Bank Of CanadaLower Price Target$7.00 -> $6.00View Rating Details
5/6/2015MizuhoReiterated RatingNeutral$5.50 -> $3.00View Rating Details
3/10/2015JMP SecuritiesLower Price TargetMarket Outperform$12.00 -> $8.00View Rating Details
2/9/2015Canaccord GenuitySet Price TargetHold$8.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
7/28/2016Q216($0.22)($0.24)$2.17 million$4.53 millionViewListenView Earnings Details
5/2/2016Q1($0.20)($0.24)$1.62 million$1.80 millionViewListenView Earnings Details
3/7/2016Q415($0.10)($0.24)$4.97 million$1.73 millionViewListenView Earnings Details
10/29/2015Q315($0.23)$0.11$1.75 million$13.90 millionViewListenView Earnings Details
8/3/2015Q215($0.26)($0.20)ViewListenView Earnings Details
5/4/2015Q115($0.28)($0.27)ViewN/AView Earnings Details
3/9/2015($0.33)($0.32)ViewN/AView Earnings Details
8/11/2014Q214($0.26)($0.24)$40.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.23)($0.22)ViewN/AView Earnings Details
3/3/2014Q413($0.17)($0.18)$4.93 million$27.60 millionViewN/AView Earnings Details
11/5/2013Q313($0.19)($0.26)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.22)($0.22)$1.73 million$0.41 millionViewListenView Earnings Details
11/6/2012Q312($0.38)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Current Year EPS Consensus Estimate: $-0.9 EPS
Next Year EPS Consensus Estimate: $-1.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.31)($0.19)($0.25)
Q2 20162($0.28)($0.23)($0.26)
Q3 20162($0.28)($0.22)($0.25)
Q4 20162($0.23)($0.23)($0.23)
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.24)($0.24)($0.24)
Q3 20171($0.23)($0.23)($0.23)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AcelRx Pharmaceuticals (NASDAQ:ACRX)
Insider Ownership Percentage: 27.40%
Institutional Ownership Percentage: 35.84%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2016Perceptive Advisors LlcMajor ShareholderSell216,500$3.92$848,680.00View SEC Filing  
9/15/2016Perceptive Advisors LlcMajor ShareholderSell392,850$3.70$1,453,545.00View SEC Filing  
5/13/2016Howard B RosenCEOBuy10,206$3.26$33,271.56View SEC Filing  
5/12/2016Mark G EdwardsDirectorBuy15,000$3.15$47,250.00View SEC Filing  
11/18/2015Perceptive Advisors LlcMajor ShareholderSell176,200$5.35$942,670.00View SEC Filing  
11/6/2015Perceptive Advisors LlcMajor ShareholderSell92,100$4.59$422,739.00View SEC Filing  
9/9/2015Perceptive Advisors LlcMajor ShareholderSell310,000$4.18$1,295,800.00View SEC Filing  
5/7/2015Mark G EdwardsDirectorBuy40,000$3.13$125,200.00View SEC Filing  
3/10/2014Mark WanDirectorSell1,000,000$12.35$12,350,000.00View SEC Filing  
11/7/2013Perceptive Advisors Llcmajor shareholderBuy200,000$6.51$1,302,000.00View SEC Filing  
11/4/2013Perceptive Advisors Llcmajor shareholderBuy155,000$6.87$1,064,850.00View SEC Filing  
11/1/2013Perceptive Advisors LlcMajor ShareholderBuy360,660$6.91$2,492,160.60View SEC Filing  
9/20/2013Guy NohraDirectorSell158,153$10.59$1,674,840.27View SEC Filing  
9/18/2013Guy NohraDirectorSell128,780$10.42$1,341,887.60View SEC Filing  
7/23/2013Perceptive Advisors LlcMajor ShareholderBuy850,000$11.65$9,902,500.00View SEC Filing  
6/6/2013Mark G EdwardsDirectorBuy10,000$8.10$81,000.00View SEC Filing  
5/28/2013Adrian AdamsDirectorBuy75,000$8.19$614,250.00View SEC Filing  
12/7/2012Mark A WanDirectorBuy2,416,918$3.31$7,999,998.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AcelRx Pharmaceuticals (NASDAQ:ACRX)
DateHeadline
smarteranalyst.com logoStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Initiates Phase 3 Study of Zalviso® in Patients with ... - Smarter Analyst (NASDAQ:ACRX)
www.smarteranalyst.com - September 28 at 3:16 PM
finance.yahoo.com logoAcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso (NASDAQ:ACRX)
finance.yahoo.com - September 28 at 3:16 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine (NASDAQ:ACRX)
finance.yahoo.com - September 28 at 8:02 AM
streetinsider.com logoAcelRx Pharma (ACRX) Initiates Phase 3 IAP312 Study of Zalviso - StreetInsider.com (NASDAQ:ACRX)
www.streetinsider.com - September 27 at 3:17 PM
4-traders.com logoAcelRx Pharmaceuticals : Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain (NASDAQ:ACRX)
www.4-traders.com - September 27 at 7:22 AM
finance.yahoo.com logoAcelRx Initiates Phase 3 Study of Zalviso® in Patients with Moderate-to-Severe Acute Post-Operative Pain (NASDAQ:ACRX)
finance.yahoo.com - September 27 at 7:22 AM
finance.yahoo.com logoFindings from AcelRx Pharmaceuticals' Phase 3 SAP301 Study of ARX-04 in Abdominoplasty Patients to be Presented at Plastic Surgery Meeting (NASDAQ:ACRX)
finance.yahoo.com - September 25 at 8:03 AM
News IconWhat's in AcelRx Pharmaceuticals Inc After Today's Huge Increase? - Post News (NASDAQ:ACRX)
www.kentuckypostnews.com - September 24 at 8:19 AM
News IconLooking Ahead for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ... - Frisco Fastball (NASDAQ:ACRX)
friscofastball.com - September 23 at 8:05 AM
smarteranalyst.com logoStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Data Presentation for ARX-04 at Plastic ... - Smarter Analyst (NASDAQ:ACRX)
www.smarteranalyst.com - September 23 at 8:05 AM
News IconTrend Analysis Report - AcelRx Pharmaceuticals, Inc.'s (ACRX) - Hot Stocks Point (NASDAQ:ACRX)
www.hotstockspoint.com - September 22 at 3:17 PM
finance.yahoo.com logoAcelRx Pharmaceuticals to Present at the Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:ACRX)
finance.yahoo.com - September 22 at 8:20 AM
News IconCowen and Company Reaffirms Hold Rating for AcelRx Pharmaceuticals (ACRX) - Petro Global News 24 (NASDAQ:ACRX)
petroglobalnews24.com - September 21 at 3:30 PM
News IconAcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Quarterly growth Review - Newburg Press (NASDAQ:ACRX)
newburghpress.com - September 17 at 8:04 AM
News IconStocks Taking Toll on Day- QUALCOMM (NASDAQ:QCOM), AcelRx Pharmaceuticals (ACRX), Winnebago Industries ... - Seneca Globe (NASDAQ:ACRX)
www.senecaglobe.com - September 16 at 3:18 PM
streetinsider.com logoAcelRx Pharma (ACRX) to Announce Topline Results From Phase 3 Study of ARX-04 (NASDAQ:ACRX)
www.streetinsider.com - September 16 at 11:58 AM
marketexclusive.com logoAcelRx Pharmaceuticals Inc (NASDAQ:ACRX) Is Gearing Towards An Unmet Need Opioid Approval (NASDAQ:ACRX)
marketexclusive.com - September 16 at 11:58 AM
finance.yahoo.com logoHas AcelRx Pharmaceuticals Hit a Home Run? (NASDAQ:ACRX)
finance.yahoo.com - September 16 at 11:57 AM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Frisco Fastball (NASDAQ:ACRX)
friscofastball.com - September 15 at 8:28 PM
thestreet.com logoHere's Why AcelRx Pharmaceuticals (ACRX) Stock Gained Today (NASDAQ:ACRX)
www.thestreet.com - September 15 at 8:28 PM
News IconWhat are Brokerage Firms Saying About AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)? - Frisco Fastball (NASDAQ:ACRX)
friscofastball.com - September 15 at 3:17 PM
insidermonkey.com logoMcDonald's Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here's Why These Stocks Are Trending ... - Insider Monkey (blog) (NASDAQ:ACRX)
www.insidermonkey.com - September 15 at 3:17 PM
News IconMcDonald’s Corporation (MCD), AcelRx Pharmaceuticals Inc. (ACRX) & More: Here’s Why These Stocks Are Trending Today (NASDAQ:ACRX)
feedproxy.google.com - September 15 at 2:15 PM
benzinga.com logoAcelRx Reports Positive Results for ARX-04 (... (NASDAQ:ACRX)
www.benzinga.com - September 15 at 12:08 PM
stockhouse.com logoAcelRx Stock Jumps 20% After Positive Results From Its Trial On ARX-04 (NASDAQ:ACRX)
www.stockhouse.com - September 15 at 12:08 PM
News IconExpectations High Around AcelRx Pharma’s (ACRX) Drug; AMREP (AXR) Posts Strong Earnings Growth (NASDAQ:ACRX)
galaxystocks.com - September 15 at 12:08 PM
finance.yahoo.com logoAcelRx Pharmaceuticals to Announce Topline Results in Phase 3 Study of ARX-04 in Patients with Post-Operative Moderate-to-Severe Acute Pain (NASDAQ:ACRX)
finance.yahoo.com - September 15 at 12:08 PM
baystreet.ca logoAcelRx Pharmaceuticals (ACRX) Soars on Trial Success (NASDAQ:ACRX)
www.baystreet.ca - September 15 at 12:08 PM
smarteranalyst.com logoCompany Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc to Announce Topline Results in Phase 3 Study of ... - Smarter Analyst (NASDAQ:ACRX)
www.smarteranalyst.com - September 14 at 8:34 PM
News IconConsensus Estimates on Earnings & Stock Price in Focus for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Shares - Frisco Fastball (NASDAQ:ACRX)
friscofastball.com - September 13 at 8:04 AM
News IconAcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) stock reaffirmed at HC Wainwright - BNB Daily (blog) (NASDAQ:ACRX)
www.baseball-news-blog.com - September 9 at 3:16 PM
News IconStock Struggling for the Quarter: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) - Post News (NASDAQ:ACRX)
www.kentuckypostnews.com - September 4 at 8:04 AM
finance.yahoo.com logoAcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events in September (NASDAQ:ACRX)
finance.yahoo.com - August 31 at 8:03 AM
News IconCrowd Perspectives & Broker Views on AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)? - Post News (NASDAQ:ACRX)
www.kentuckypostnews.com - August 30 at 3:17 PM
streetinsider.com logoAcelRx Pharma (ACRX) to Present Data from Phase 3 SAP302 Study of ARX-04 as Pain Treatment (NASDAQ:ACRX)
www.streetinsider.com - August 30 at 12:05 PM
finance.yahoo.com logoAcelRx Pharmaceuticals Presents Results from Phase 3 Study of ARX‑04 in the Emergency Department at the International Society for Burn Injuries (NASDAQ:ACRX)
finance.yahoo.com - August 29 at 3:34 PM
smarteranalyst.com logoStock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Results from Phase 3 Study of ARX‑04 in the ... - Smarter Analyst (NASDAQ:ACRX)
www.smarteranalyst.com - August 29 at 8:03 AM
investornewswire.com logoWill AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Hit $11.25 Price Target? - Investor Newswire (NASDAQ:ACRX)
www.investornewswire.com - August 19 at 8:20 PM
rttnews.com logoAUPH Loses Aura, PETX Scores Hat Trick, ACRX Meets Trial Goal (NASDAQ:ACRX)
www.rttnews.com - August 16 at 11:54 AM
feeds.benzinga.com logoAcelRx Pharmaceuticals' ARX-04 Final Stage Study Meets Primary Endpoint (NASDAQ:ACRX)
feeds.benzinga.com - August 15 at 10:37 AM
streetinsider.com logoAcelRx Pharma (ACRX) Says ARX-04 Phase 3 Met Primary Endpoint in Trauma/Injury Pain Reduction - StreetInsider.com (NASDAQ:ACRX)
www.streetinsider.com - August 15 at 10:32 AM
finance.yahoo.com logoAcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain (NASDAQ:ACRX)
finance.yahoo.com - August 15 at 10:32 AM
finance.yahoo.com logo7:01 am AcelRx reports the topline results from the Phase 3 SAP302 trial met its primary endpoint (NASDAQ:ACRX)
finance.yahoo.com - August 15 at 10:32 AM
biz.yahoo.com logoACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib (NASDAQ:ACRX)
biz.yahoo.com - August 15 at 10:32 AM
capitalcube.com logoETF’s with exposure to AcelRx Pharmaceuticals, Inc. : August 8, 2016 (NASDAQ:ACRX)
www.capitalcube.com - August 8 at 3:18 PM
equities.com logoAcelRx Pharmaceuticals Inc. (ACRX) Drops 5.32% on August 04 ... - Equities.com (NASDAQ:ACRX)
www.equities.com - August 6 at 3:18 PM
investornewswire.com logoStrong Sell Calls For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) At 0 - Investor Newswire (NASDAQ:ACRX)
www.investornewswire.com - August 5 at 8:42 PM
capitalcube.com logoAcelRx Pharmaceuticals, Inc. :ACRX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:ACRX)
www.capitalcube.com - August 5 at 3:16 PM
nasdaq.com logoAcelRx Pharmaceuticals (ACRX) in Focus: Stock Jumps 5.3% - Nasdaq (NASDAQ:ACRX)
www.nasdaq.com - August 4 at 3:18 PM
finance.yahoo.com logoACELRX PHARMACEUTICALS INC Financials (NASDAQ:ACRX)
finance.yahoo.com - August 4 at 3:18 PM

Social

AcelRx Pharmaceuticals (NASDAQ:ACRX) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff